Skip to Content
Merck
  • Neuromyelitis optica spectrum disorder: 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography findings--case report.

Neuromyelitis optica spectrum disorder: 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography findings--case report.

Neurologia medico-chirurgica (2012-10-26)
Hirofumi Oyama, Shigeru Miwa, Tomoyuki Noda, Atsuhiro Sobajima, Akira Kito, Hideki Maki, Kenichi Hattori, Kentaro Wada
ABSTRACT

A 51-year-old female with a history of rheumatoid arthritis rapidly developed anterior neck pain and paresis in the left upper and lower extremities and right lower extremity, sensory disturbance in the left upper and lower extremities, and bladder and rectal disorder. Adduction of the left eye and abduction of the right eye were also disturbed. Spinal magnetic resonance imaging demonstrated severe edema in the C1-T5 levels, which then deteriorated rapidly over 3 days, and lesions enhanced with gadolinium in the C1-C3 and C5-T3 levels. 2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography study demonstrated the inflammatory sites as segmental enhanced accumulation in the C1-C3, C5-C6, and T1 levels. The serum anti-aquaporin 4 antibody level was positive and she was diagnosed with neuromyelitis optica spectrum disorder. Marked improvement in the neurological conditions, concomitant with reduced spinal cord edema, was obtained by steroid pulse therapy.

MATERIALS
Product Number
Brand
Product Description

Methylprednisolone hydrogen succinate, European Pharmacopoeia (EP) Reference Standard
USP
Methylprednisolone hemisuccinate, United States Pharmacopeia (USP) Reference Standard
Methylprednisolone hydrogen succinate for performance test, European Pharmacopoeia (EP) Reference Standard